RNA Formulation Resources

51. Development And Optimization Of LNP Formulations 12/6/2024

    The production of lipid nanoparticles (LNPs) is a process that demands robustness, scalability, and reproducibility. Examine the impact of key operational parameters on the efficacy of LNPs.

52. How To Make The Best LNPs 1/22/2024

    There are various factors that require careful consideration throughout the process of formulating LNPs and utilizing them for successful mRNA delivery and translation.

53. Exploring Osmolality As A CQA Within RNA Therapeutics 10/3/2023

    Discover how osmolality can be applied throughout the bioprocessing workflow for RNA, and recognize the importance of this sensitive measurement, from formulation optimization to cryopreservation techniques.

54. Oligonucleotide Purification And Synthesis 1/27/2026

    Examine how a 21‑mer oligo was synthesized and purified through systematic resin screening, method optimization, and successful scale‑up to build reliable, high‑purity chromatography workflows.

55. CQA Assessment Of LNP-Encapsulated IVT mRNA 4/21/2025

    Learn more about issued guidelines on Critical Quality Attributes for IVT mRNA vaccines and biotherapeutics to focus on drug substance and LNP-encapsulated drug product assessment using an analyzer system.

56. Stabilization Of RNA-Loaded Lipid Nanoparticles By Lyophilization 8/15/2025

    Discover how lyophilization enhances RNA-based therapeutics by enabling storage at higher temperatures, which simplifies cold-chain logistics while preserving nanoparticle integrity and biological activity.

57. A Novel RNA Lipid Nanoparticle Platform: Gene-Edited CAR T Cells For Off-The-Shelf Cancer Therapy 4/14/2022

    We report on the use of a novel lipid nanoparticle (LNP) reagent in a validated protocol to achieve successful complex gene editing in primary T cells with high efficiency while maintaining high cell viability.

58. Accelerate LNP Manufacturing With Automated Process Development 2/5/2026

    Manual LNP formulation introduces process variability that threatens particle quality and yield. As programs scale toward clinical production, maintaining strict control over CQAs becomes essential.

59. How Operational Efficiency Shapes Late-Phase Manufacturability 6/26/2026

    Prioritize operational efficiency over early-stage flexibility to scale advanced therapies. Standardized workflows and qualified shipping lanes reduce variability for predictable late-phase success.

60. Standardize Scale-Up And Reduce Time To Market With Mixing Cartridges 7/21/2023

    Despite the momentum of the RNA-LNP therapeutic market, significant manufacturing challenges remain. However, the right mixing could solve three of these key challenges regarding instrumentation.